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Summary A 52-year-old man developed therapy-related acute myeloid leukemia 
(AML) following prolonged immunosuppression with azathioprine for 
polymyositis. Karyotypic analysis showed deletions of the short arm of 
chromosome 7 and the long arm of chromosome 5. The importance of 
recognizing this potential complication while treating benign rheumatological 
and immunological diseases with purine analogues like azathioprine is 
emphasized. Therapy-related AML is a poor prognostic group that does not 
respond favourably to standard induction therapy. 
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Therapy-related acute myeloid leukaemia is a well recognized complication 
following cytotoxic therapy with alkylating agents (cyclophosphamide, busulfan, 
chlorambucil, melphalan and nitrogen mustards) in various malignant and benign 
conditions (Louie & Schwartz 1978; Frisch, Bart1 & Chaichik 1986). Rarely, 
purine analogues like azathioprine have been known to cause lymphomas, solid 
tumours and acute myeloid leukaemia in patients on long-term immunosuppres- 
sion for various conditions like primary biliary cirrhosis (Louie et al. 1978), 
rheumatoid arthritis (Seidenfeld et al. 1984), systemic lupus erythematosus 
(Vasquez et al. 1992), systemic sclerosis (Tulliez et al. 1974) and renal transplant 
recipients (Hoy, Packman & Freeman 1982). 
We report a case of acute myeloid leukaemia following treatment of poly- 
myositis with azathioprine. 
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Case report 
A 52-year-old man was admitted to the University of Michigan Medical Center in 
February 1993 with a four-week history of fever, night sweats, fatigue and cough 
associated with pancytopenia. 
His past medical history was significant for polymyositis and Hashimoto's 
thyroiditis diagnosed in 1984 when he presented with neck muscle weakness, 
inability to keep his head up, difficulty in rising from the chair and raising his 
arms above his head. Examination was significant for decreased strength in the 
sternocleidomastoids, weak head extension, and decreased bulk in the shoulder 
muscles and biceps. Electromyography was consistent with a chronic myopathy 
and muscle biopsy showed mild focal degeneration and mononuclear cell 
infiltration. 
Creatine phosphokinase (CPK) levels were 346 U/l (normal 30-225). Thyroid 
function tests were consistent with hypothyroidism with TSH of 12 mU/1 (normal 
0-7) and serum T, 0.04 mmoles/l (normal 0.06-0.15). He also had high titre 
anti-microsomal antibodies with titres of 1 in 6400 (normal less than 1 in 400). 
ESR was 54 mm/h. Autoantibody screen was negative. Complement levels were 
normal. He was initially treated with prednisone and thyroxine replacement and 
subsequently changed to azathioprine because he developed diabetic coma while 
on the steroids. He was started on 250mg of azathioprine daily in 1984 and 
reduced to 100 mg in 1989 and tapered to 50 mg in 1991. The symptoms of 
polymyositis were well controlled on this immunosuppressive regime but repeat 
electromyography continued to show evidence of ongoing inflammation and 
denervation in the form of high amplitude fibrillation potentials in the paraspinal 
muscles. He was hence maintained on azathioprine. He was regularly followed up 
with CPK levels and full blood counts. The counts were normal till February 1993 
when he was found to have pancytopenia. 
Physical examination in 1993 revealed an obese man who was febrile with a 
temperature 100.4"F, pulse 78/min, respiratory rate 16/min and blood pressure 
138/70 mm Hg. He had oropharyngeal petechiae and a 1 cm mobile right axillary 
lymph node. There was no hepatosplenomegaly. There was no obvious muscle 
weakness. 
Laboratory examination revealed haemoglobin 8.6 g/dl, WBC 2.7 x 109/dl, 
platelets 13 x 109/dl and a differential count of segs 14%, bands 5%, blasts 7'10, 
eosinophils 3%, monocytes 3 %  and lymphocytes 57%. The absolute neutrophil 
count was 0.5 x 109/dl. Liver function tests were normal. Bone marrow examina- 
tion was consistent with acute myeloid leukaemia (FAB-AML, MO). Flow 
cytometric immunophenotypic analysis showed CD 13, CD 33, CD 34, CD 45, 
HLA Dr, CD 1 l c  and CD 15 positivity consistent with acute myeloid leukaemia. 
Cytogenetics (Figure 1) identified 13 of 18 cells analysed to be abnormal with the 
karyotype 46, XY, del(5) (q 21), der (7) t(7;?) (p 22; ?); - 12, - 17, +mar, +mar. 
Five cells had a normal karyotype with a normal male chromosome complement. 
The presence of abnormalities in addition to those on chromosomes five and 
seven were interpreted as signifying a poor prognosis. 
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Figure 1. Karyotype showing the deletion of part of the long arm of chromosome 5 and derivative 
chromosome 7 (arrows) and the two marker chromosomes, labelled marl and mar2. These 
abnormalities were seen in 13 of 18 cells; a 46, XY, normal karyotype was seen in the remaining five 
cells. 
He was treated on a standard induction regime with daunorubicin at 45 mg/m2 
on days 1 to 3 and cytosine arabinoside at 100 mg/m2 on days 1 to 7. The repeat 
bone marrow examination performed after the counts had recovered following 
induction showed hypercellularity and the presence of all three cell lines with no 
residual leukemia; in addition there was hyperplasia, atypicality and clustering of 
megakaryocytes consistent with either a myelodysplastic process or an effect of 
cytotoxic drugs. Repeat cytogenetics revealed the persistence of the abnormal 
karyotype in 1 of 15 cells studied. He received two cycles of consolidation 
chemotherapy with daunorubicin and cytosine arabinoside and was in complete 
remission for two months when he relapsed. All the courses of chemotherapy were 
complicated by severe hypotension and febrile neutropenia. 
Discussion 
The occurrence of therapy-related acute myeloid leukaemia in the setting of 
prolonged immunosuppression for benign rheumatological and immunological 
conditions is an important complication to be recognized (Levine & Bloomfield 
1992). The occurrence of this complication following administration of cytotoxic 
agents especially alkylating agents for a primary malignancy have been previously 
described (Sheibani et al. 1980). The alkylating agents have been the main agents 
responsible in causing MDS/AML in nonhaematological diseases. Recently, 
epipodophyllotoxins and cisplatinum have also been implicated (Levine et al. 
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1992). Occurrence of secondary myelodysplastic syndrome or acute myeloid 
leukaemia (MDS/AML) following the use of fluorinated pyrimidines, cytidine 
analogues, antifolates, purine analogues like 6-mercaptopurine and azathioprine, 
anthracyclines and plant alkaloids have been rare, published as isolated case 
reports. 
The occurrence of AML in azathioprine treated patients was first described in 
1974 (Silvergleid & Schrier 1974) and since then there have been only few cases 
reported (Alexson & Brandt 1977; Gilmore, Holden & Rodan 1977; Vismans et al. 
1980). We describe a patient who presented with pancytopenia and acute myeloid 
leukaemia following nine years of treatment with azathioprine for polymyositis. 
We were not able to document morphologically any preceding myelodysplastic 
process in this patient. The minimal dysplastic changes seen in the post-induction 
marrow could be due to the cytotoxic drugs used during induction therapy. The 
presence of cytogenetic abnormalities of chromosomes 5 and 7 are seen both in 
therapy-related MDS and AML and cannot be used to distinguish them reliably 
(Johansson et al. 1991; Heim 1992). 
Long term immunosuppression with purine analogues could be complicated 
by acute myeloid leukaemia. Prognosis of therapy-related AML is poor and only 
allogenic bone marrow transplantation offers a curative approach (Longmore 
et ai. 1990). 
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